Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.

Abstract

This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.

• Authors: David R Andes, Mahmoud A Ghannoum, Pranab K Mukherjee, Laura L Kovanda, Qiaoyang Lu, Mark E Jones, Anne Santerre Henriksen, Christopher Lademacher, William W Hope
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 63 Issue 1 (01 2019) ISSN: 1098-6596 [Electronic] United States
• PMID: 30373791 (Publication Type: Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Andes et al.

Chemical References

• Antifungal Agents
• Nitriles
• Pyridines
• Triazoles
• isavuconazole
• Voriconazole

Topics

• Antifungal Agents (therapeutic use)
• Aspergillosis (drug therapy, microbiology, mortality)
• Aspergillus (drug effects, isolation & purification)
• Humans
• Invasive Fungal Infections (drug therapy, microbiology)
• Microbial Sensitivity Tests
• Nitriles (therapeutic use)
• Pyridines (therapeutic use)
• Triazoles (therapeutic use)
• Voriconazole (therapeutic use)